Drug survival of secukinumab for psoriasis in a real-world setting

被引：16

作者：

Lee, Erica B. ^{[1
]}

Amin, Mina ^{[2
]}

Egeberg, Alexander ^{[3
]}

Wu, Jashin J. ^{[4
]}

机构：

[1] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA

[2] Univ Calif Riverside, Sch Med, Riverside, CA 92521 USA

[3] Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Hellerup, Denmark

[4] Kaiser Permanente, Los Angeles Med Ctr, Dept Dermatol, Los Angeles, CA 90027 USA

来源：

JOURNAL OF DERMATOLOGICAL TREATMENT | 2019年 / 30卷 / 02期

关键词：

EFFICACY;

D O I：

10.1080/09546634.2018.1473838

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：150 / 151

页数：2

共 5 条

[1]

Bissonnette R, 2018, J EUR ACAD DERMATOL

[2] Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis [J].

Egeberg, A. ;

Ottosen, M. B. ;

Gniadecki, R. ;

Broesby-Olsen, S. ;

Dam, T. N. ;

Bryld, L. E. ;

Rasmussen, M. K. ;

Skov, L. .

BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) :509-519

[3] Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study [J].

Georgakopoulos, Jorge R. ;

Ighani, Arvin ;

Phung, Michelle ;

Yeung, Jensen .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (05) :1019-1020

[4] Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks [J].

Huang, Yuan Yu Michael ;

Ruth, Jennifer Shuley ;

Hsu, Sylvia .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (04) :E169-E169

[5]

Van den Reek JMPA, 2018, ACTA DERM VENEROL

← 1 →